HALO - HALOZYME THERAPEUTICS, INC.

QQQ $ 479.20 $ 0.43 (0.09 %)

DIA $ 407.51 $ -1.51 (-0.37 %)

SPY $ 556.52 $ -4.40 (-0.78 %)

TLT $ 98.19 $ 0.00 (0 %)

GLD $ 229.39 $ -2.78 (-1.2 %)

Previous Close

$ 61.64

Open

Bid

$ 61.64 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 32.83 - $ 62.58

Volume

918,699

Average Volume

Market Cap

7.81B

Beta (5Y Monthly)

$ 1.02

PE Ratio (TTM)

$ 23.15

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-20-2024	12-31-2023	10-K
4	11-06-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-21-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	02-22-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	02-23-2021	12-31-2020	10-K
16	11-02-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-11-2020	03-31-2020	10-Q
19	02-24-2020	12-31-2019	10-K
20	11-12-2019	09-30-2019	10-Q
21	08-06-2019	06-30-2019	10-Q
22	05-07-2019	03-31-2019	10-Q
23	02-21-2019	12-31-2018	10-K
24	11-06-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	02-20-2018	12-31-2017	10-K
28	11-07-2017	09-30-2017	10-Q
29	08-08-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	02-28-2017	12-31-2016	10-K
32	11-07-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-09-2016	03-31-2016	10-Q
35	02-29-2016	12-31-2015	10-K
36	11-09-2015	09-30-2015	10-Q
37	08-10-2015	06-30-2015	10-Q
38	05-11-2015	03-31-2015	10-Q
39	03-02-2015	12-31-2014	10-K
40	11-10-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

how-is-the-market-feeling-about-halozyme-therapeutics

How Is The Market Feeling About Halozyme T...
08/20/2024 13:15:24

Benchmark Reiterates Buy on Halozyme Thera...
08/08/2024 15:50:09

Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $60 price target.

HC Wainwright & Co. Reiterates Buy on Halo...
08/08/2024 10:50:15

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...

TD Cowen Maintains Buy on Halozyme Therape...
08/07/2024 21:13:31

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $59...

Morgan Stanley Maintains Overweight on Hal...
08/07/2024 16:25:32

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price t...

Halozyme Therapeutics Sees FY24 EPS $3.65-...
08/06/2024 20:13:26

Financial Outlook for 2024The Company is reiterating its financial guidance for 2024, which was increased on June 6, 2024 as a ...

Halozyme Therapeutics Q2 Adj $0.91 Beats $...
08/06/2024 20:02:11

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of...

JP Morgan Maintains Overweight on Halozyme...
08/06/2024 16:21:00

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target fr...

halo---analyzing-halozyme-therapeuticss-short-interest

(HALO) - Analyzing Halozyme Therapeutics's...
08/01/2024 17:30:16

Analyst Scoreboard: 14 Ratings For Halozym...
08/01/2024 12:01:38

HC Wainwright & Co. Reiterates Buy on Halo...
08/01/2024 10:51:35

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...

Goldman Sachs Maintains Neutral on Halozym...
07/22/2024 13:33:31

Goldman Sachs analyst Graig Suvannavejh maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price ta...

What 13 Analyst Ratings Have To Say About ...
07/16/2024 12:00:22

HC Wainwright & Co. Reiterates Buy on Halo...
07/16/2024 11:46:14

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...

HC Wainwright & Co. Reiterates Buy on Halo...
06/26/2024 16:19:31

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...

Benchmark Maintains Buy on Halozyme Therap...
06/25/2024 12:34:47

Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from...

Halozyme's OCREVUS SC Gets European Approv...
06/25/2024 07:11:23

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Roche received European Commission (EC) mar...

Decoding 12 Analyst Evaluations For Halozy...
06/24/2024 12:01:23

HC Wainwright & Co. Reiterates Buy on Halo...
06/24/2024 10:09:58

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...

novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio

Novavax And Agios Pharmaceuticals Were Amo...
06/09/2024 18:29:27

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...